CRBP 8-K: Fda approval
Corbus Pharmaceuticals
Filed with the SEC on · accession 0001193125-26-462186
CRBP filed a 8-K (current report) with the SEC on Nov 16, 2026. Corbus Pharmaceuticals announced additional positive data from its CANYON-1 Phase 1b clinical trial of CRB-913 for obesity, showing statistically significant and clinically meaningful weight loss at all three doses with a favorable safety profile.
Summary of the filing
Corbus Pharmaceuticals announced additional positive data from its CANYON-1 Phase 1b clinical trial of CRB-913 for obesity, showing statistically significant and clinically meaningful weight loss at all three doses with a favorable safety profile. The data were presented at ObesityWeek 2026.
Key details
✦ Ask GOAX AI about this filing — what it means for CRBP, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CRBP?
Click hereFrequently asked questions
What did CRBP file with the SEC on Nov 16, 2026?
CRBP filed a 8-K (Fda approval). Corbus Pharmaceuticals announced additional positive data from its CANYON-1 Phase 1b clinical trial of CRB-913 for obesity, showing statistically significant and clinically meaningful weight loss at all three doses with a favorable safety profile. The data were presented at ObesityWeek 2026.
What does a fda approval mean for CRBP stock?
For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other CRBP SEC filings
- SCHEDULE 13G · SEC filingNov 13, 2026
- 8-K · SEC filingNov 10, 2026
- 10-Q · SEC filingNov 10, 2026
- SCHEDULE 13G/A · SEC filingNov 2, 2026
- SCHEDULE 13G/A · SEC filingOct 29, 2026
- 8-K · SEC filingOct 15, 2026
- SCHEDULE 13G · SEC filingSep 30, 2026
- 8-K · Fda approvalSep 14, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- 424B5 · Secondary offeringAug 7, 2026
Get alerts when CRBP files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days